Log in to your Inderes Free account to see all free content on this page.
Cereno Scientific
8.26 SEK
+3.12 %
Less than 1K followers
CRNO B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+3.12 %
+13.93 %
-12.59 %
-23.09 %
+50.18 %
+32.27 %
+307.90 %
+334.74 %
+37.41 %
Cereno Scientific is active in biotechnology. The company specializes in drug development for common and rare cardiovascular diseases. The main drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension (PAH), as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. The head office is in Mölndal with offices also in North America.
Read moreMarket cap
2.56B SEK
Turnover
5.65M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.2.
2026
Annual report '25
All
Webcasts
Press releases
3rd party
ShowingAll content types
Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027
Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio